Phase 2b oral obesity trial
- Reported quantity
- 1 mg, 5 mg, 10 mg, 20 mg and 30 mg oral arms
- Frequency
- Once daily
- Study duration
- 24 weeks
No arm separated from placebo on weight endpoints in the published 24-week study.
Protocols · Growth Hormone
AOD-9604: literature-reported ranges
AOD-9604 is the C-terminal fragment of growth hormone, developed as an oral anti-obesity candidate. Its phase 2 programme is public and, importantly, its larger trial did not separate from placebo — an outcome worth as much attention as the protocol.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- hGH fragment 176-191
- Reported half-life
- Under 30 minutes
- Routes used in the literature
- Oral and subcutaneous in the human trials; topical/intra-articular in later work
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Earlier 12-week dose-ranging
- Reported quantity
- 1–30 mg orally
- Frequency
- Once daily
- Study duration
- 12 weeks
The apparent effect in the shorter study did not replicate at 24 weeks.
Intra-articular and cartilage research
- Reported quantity
- 0.25–2.5 mg per joint in the reported animal work
- Frequency
- Weekly
- Study duration
- 3–8 weeks
This later research direction is unrelated to the obesity programme.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
AOD-9604 · 2 mg Vial
AOD-9604 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 0.667 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~ 0.667 mg/mL (667 mcg/mL) concentration.
- Typical daily range
- 300–500 mcg once daily (gradual titration).
- Easy measuring
- At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Standard / Gradual Approach (3 mL = ~0.667 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–12 | 500 mcg | 75 units (0.75 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size AOD-9604 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
AOD-9604 · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit | 300 mcg = | 500 mcg = |
|---|---|---|---|---|
| 5 mg | 1.67 mg/ml | 17 mcg | 18 units | 30 units |
| 10 mg | 3.33 mg/ml | 33 mcg | 9.0 units | 15 units |
Unit columns use the range reported for this compound (300 mcg–500 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 5 mg vial in 2 mL of bacteriostatic water gives 2.5 mg/mL.
Open the reconstitution calculatorHow to read these figures
- The most useful published fact about this compound is a negative result — read the 24-week outcome, not just the design.
- It lacks the IGF-1-raising activity of full-length GH, which is often presented as an advantage and also explains the weak effect.
- Oral arms mean formulation matters enormously; a research powder is not the trial formulation.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Stier H, Vos E, Kenley D · J Endocrinol Metab · 2013 · DOI 10.4021/jem157w
Reviews human safety/tolerability data for AOD9604 administered at doses used in prior obesity clinical trials (up to 1 mg/day and higher exploratory doses).
View the record - [2]Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Moré MI, Kenley D · J Endocrinol Metab · 2014 · URL jofem.org/index.php/jofem/article/view/213/278
Describes oral administration of AOD9604 at specified milligram doses and its metabolic fate/safety in human and preclinical models.
View the record
Search the databases yourself
Read the AOD-9604 research briefOther growth hormone compounds
CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogueCJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blendCJC-1295 with DACGHRH analogue with albumin-binding drug affinity complexGHRP-2Hexapeptide GH secretagogue
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.